Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -226.1% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 18.0 | n/a |
Pr/Book | n/a |
Latest | F'cast | |
---|---|---|
Revenue | n/a | -100.0% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Apr-19 | n/a | (6.71) | (1.42)p | n/a | n/a | n/a | n/a | 0.0% |
30-Apr-20 | n/a | (6.77) | (1.18)p | n/a | n/a | n/a | n/a | 0.0% |
30-Apr-21 | n/a | (16.81) | (2.28)p | n/a | n/a | n/a | n/a | 0.0% |
30-Apr-22 | n/a | (6.27) | (0.56)p | n/a | n/a | n/a | n/a | 0.0% |
30-Apr-23 | 5.27 | (14.30) | (1.50)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Apr-24 | n/a | (17.37) | (1.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Apr-25 | n/a | (14.63) | (1.51)p | n/a | n/a | n/a | 0.33p | 0.0% |
30-Apr-26 | n/a | (15.10) | (1.51)p | n/a | n/a | n/a | 1.00p | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
First iSCIB1+ patient dosed | 26-Mar-2024 | 12:22 | RNS |
Appointment of Sath Nirmalananthan to the Board | 14-Mar-2024 | 11:17 | RNS |
Presenting at Next-Gen Immuno-Oncology Conference | 04-Mar-2024 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 10.07p |
Change Today | -0.18p |
% Change | -1.74 % |
52 Week High | 20.50 |
52 Week Low | 8.15 |
Volume | 36,075 |
Shares Issued | 927.82m |
Market Cap | £93.44m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
10:34 | 11,547 @ 10.39p |
09:24 | 2 @ 10.39p |
09:21 | 1 @ 10.39p |
09:19 | 9 @ 10.39p |
09:17 | 7 @ 10.38p |
CEO | Lindy Durrant |
CFO | Sath Nirmalananthan |
You are here: research